| 崔江漫,狄宁宁,王姣,等.重组人脑利钠肽联合沙库巴曲缬沙坦治疗老年慢性心力衰竭伴快速心房颤动患者的效果及安全性评价[J].中国临床保健杂志,2025,28(3):389-393. |
| 重组人脑利钠肽联合沙库巴曲缬沙坦治疗老年慢性心力衰竭伴快速心房颤动患者的效果及安全性评价 |
| The safety and effectiveness of using sacubatro valsartan in combination with neoactivin for the treatment of elderly individuals suffering from fast atrial fibrillation and congestive heart failure |
| 投稿时间：2024-12-20 |
| DOI：10.3969/J.issn.1672-6790.2025.03.022 |
| 中文关键词: 心力衰竭 心房颤动 利钠肽,脑 血管紧张素受体拮抗剂 老年人 |
| 英文关键词: Heart failure Atrial fibrillation Natriuretic peptide,brain Angiotensin receptor antagonists Aged 〖FL |
| 基金项目:河北省邢台市科技局基金项目(2020ZC178) |
|
| 摘要点击次数: 319 |
| 全文下载次数: 337 |
| 中文摘要: |
| 目的 探讨重组人脑利钠肽联合沙库巴曲缬沙坦治疗老年慢性心力衰竭伴快速心房颤动患者的效果及安全性。方法 前瞻性研究。选取2020年11月至2023年11月邢台市中心医院收治的160例慢性心力衰竭伴快速心房颤动患者为研究对象。根据治疗方案的不同分为对照组(77例,在标准治疗基础上加沙库巴曲缬沙坦治疗)及研究组(83例,在对照组基础上联合重组人脑利钠肽治疗),比较2组患者治疗效果,治疗前后的血清指标[血红蛋白(Hb)、总胆红素(TBIL)、直接胆红素(DBIL)、血肌酐(SCr)、估算肾小球滤过率(eGFR)、三酰甘油(TG)、D-二聚体(D-dimer)、总胆固醇(TC)、左心房内径(LAD)、氨基末端B型脑钠肽(NT-proBNP)、左心室内径(LVD)、左心室射血分数(LVEF)]水平差异及相关不良反应的发生情况,再住院、全因死亡的终点事件发生率。结果 研究组患者治疗的总有效率显著高于对照组(P<0.05)；研究组患者TG、TC、TBIL、DBIL及NT-proBNP、LAD、LVD、SCr水平均低于对照组(P<0.05)；eGFR、LVEF水平均明显高于对照组(P<0.05)。2组再住院、全因死亡的终点事件发生率及药物治疗相关不良反应发生率比较,差异无统计学意义(P>0.05)。结论 对老年慢性心力衰竭伴快速心房颤动患者应用重组人脑利钠肽联合沙库巴曲缬沙坦治疗,能缓解患者临床症状,加快心肾功能恢复,具有较好的临床疗效。 |
| 英文摘要: |
| Objective To explore the efficacy and safety of treating elderly patients with congestive heart failure and rapid atrial fibrillation using a combination of sacubatro valsartan and neoactivin.Methods This study was a prospective study,selecting 160 patients with congestive heart failure and rapid atrial fibrillation admitted to Xingtai Central Hospital from November 2020 to November 2023.All patients were treated with standard anti heart failure drugs.According to different treatment plans,the patients were divided into a control group (77 cases,treated with sacubitril valsartan on the basis of standard treatment) and a study group (83 cases,treated with neoactivin on the basis of the control group).The clinical efficacy,serum indexes[hemoglobin (Hb),total bilirubin (TBIL),serum creatinine (SCr),estimated glomerular filtration rate (eGFR),triglyceride (TG),D-dimer,left atrial diameter (LAD),total cholesterol (TC),N-terminal pro-brain natriuretic peptide (NT-proBNP),Left ventricle diameter (LVD),direct bilirubin(DBIL),left ventricular ejection fraction (LVEF)]were compared between the two groups before and after treatment.Comparison of the incidence of adverse events in the two groups,the incidence of endpoint events of rehospitalization and all-cause mortality.Results Compared to the control group,the study group′s overall effective rate was noticeably greater(P<0.05).In comparison to the control group,the levels of TG,TC,TBIL,DBIL,NT-proBNP,LAD,LVD and SCr were reduced in the study group (P<0.05).Compared to the control group,the values of eGFR and LVEF were significantly higher (P<0.05).The incidence of end point events,such as rehospitalization,all-cause death,and adverse reactions related to pharmacological therapy,did not significantly differ between the two groups(P>0.05).Conclusions When neoactivin and sacubatro valsartan are used together to treat elderly patients with congestive heart failure and fast atrial fibrillation,the patients′ clinical symptoms can be alleviated,heart and kidney function can be restored more quickly,and have good clinical efficacy. |
|
查看全文
|
| 关闭 |
|
|
|